PCSA Processa Pharmaceuticals, Inc.
Price Chart
Executive Summary
Six PCSA insiders, including the CEO, CFO, and four other C-suite officers, made clustered open-market purchases totaling ~$30K at $2.97/share on April 15, 2026. This is a unanimous insider-buying cluster at a micro-cap ($8M market cap) clinical-stage biotech, representing ~0.4% of market cap — a notable signal when all senior insiders voluntarily commit cash in concert.
Key Financial Metrics
Actionable Insight
The unanimous C-suite insider buying cluster at a low-float micro-cap is a strong contrarian bullish signal. Per academic literature, cluster buys from top executives at small-cap biotechs are among the most predictive insider patterns, often preceding positive pipeline catalysts or near-term value events. Monitor for upcoming clinical data readouts, regulatory updates, or financing news that may have motivated this synchronized buying. The stock's low dollar-purchase size ($30K) but high proportional signal (~0.4% of cap) suggests insiders view current ~$3/share as a favorable entry point ahead of a catalyst.
Key Facts
- Six insiders bought a total of ~10,100 shares at $2.97, aggregate $30K.
- CFO, CEO, Pres. R&D, CAO, Chief Business Strategy Officer, and Chief Development Officer all bought on the same day.
- Total insider cluster value represents ~0.4% of PCSA's $8M market cap.
- No open-market sales detected in the cluster — all buys.
- All trades are open-market purchases (code P), not option exercises or grants.
- Recent 30-day insider activity showed 6 buys totaling $31K — this cluster accounts for the bulk.
Financial Impact
$30K in open-market insider purchases, ~0.4% of PCSA's $8M market cap.
Risk Factors
- Clinical-stage biotech with $8M market cap carries inherent binary risk — pipeline failure could wipe out equity.
- Insider purchases at this scale ($30K) are modest in absolute dollars; insiders at micro-caps often make small token buys.
- Historical PCSA insider buying reports showed negative T+20 alpha (-9.46% avg), indicating prior cluster reads underperformed.
- Score calibration data shows score-5/6 filings on this cohort have only 32% observed probability of up-move at T+20.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PCSA-1779226326165 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
11d ago
|
Insider Cluster
| $2.92 $2.80 | ▼ −4.11% | ▼ −3.39% | $2.17 (−25.68%) |
|
May 19, 2026
24d ago
|
Insider Cluster
| $2.61 $2.57 | ▼ −1.72% | ▼ −1.92% | $2.17 (−16.86%) |
|
May 19, 2026
24d ago
|
Insider Cluster
| $2.61 $2.57 | ▼ −1.72% | ▼ −1.92% | $2.17 (−16.86%) |
|
Apr 30, 2026
6w ago
|
Insider Cluster
| $2.70 $2.55 | ▼ −5.56% | ▼ −5.78% | $2.17 (−19.63%) |
|
Apr 15, 2026
8w ago
|
Insider Cluster
| $2.96 $3.18 | ▲ +7.43% | ▲ +7.18% | $2.17 (−26.69%) |
|
Mar 31, 2026
10w ago
|
Insider Cluster
| $2.53 $2.60 | ▲ +3.09% | ▲ +2.34% | $2.17 (−14.06%) |
|
Mar 31, 2026
10w ago
|
Insider Cluster
| $2.53 $2.60 | ▲ +3.09% | ▲ +2.34% | $2.17 (−14.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access